Acuta Capital Partners, LLC Aldeyra Therapeutics, Inc. Transaction History

Acuta Capital Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$3.25 - $5.17 $1.63 Million - $2.59 Million	-500,000 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$3.5 - $9.63 $1.75 Million - $4.82 Million	500,000 New	500,000 $2 Million
Q1 2021 May 17, 2021	SELL	$6.53 - $14.42 $1.26 Million - $2.78 Million	-192,500 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$6.31 - $8.13 $9.18 Million - $11.8 Million	-1,454,200 Reduced 88.31%	192,500 $1.32 Million
Q3 2020 Nov 16, 2020	BUY	$4.0 - $7.53 $3.03 Million - $5.7 Million	756,700 Added 85.02%	1,646,700 $12.2 Million
Q2 2020 Aug 14, 2020	BUY	$1.97 - $5.05 $1.75 Million - $4.49 Million	890,000 New	890,000 $3.71 Million

117

36.2M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $320M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.